Synopsis:

Sakar Healthcare jumped sharply after securing 9 new approvals for its oncology drugs across Europe and emerging markets, taking the total to 11. This move strengthens its global presence and opens new export opportunities for its cancer treatment portfolio.

The shares of this leading pharmaceutical company are in focus after receiving new approval for its injection to treat cancer. In this article, we will dive more into the details and their significance.

With a market capitalization of Rs 809 crore, the shares of Sakar Healthcare Ltd made a day high of Rs 376.60 per share, up by 4 percent from its day’s low price of Rs 360.55 per share. Over the past five years, the stock has delivered a robust return of 333 percent, outperforming NIFTY 50’s return of 108 percent.

Abou

See Full Page